But many existing models fall short of adhering to established best practices for economic evaluation, the review authors ...

Five-year survival rates improved greatly because of immunotherapy and other advances, according to the American Cancer ...

Five-year survival rates improved greatly because of immunotherapy and other advances, according to the American Cancer ...

Ozempic, Rybelsus and Wegovy top the list of the newest drugs selected for Medicare Part price negotiation, part of the ...

Cancer mortality rates have decreased by 34% overall, but incidence rates for women of all ages continue to rise, according ...

Berge will serve in this role through the end of 2026, marking another milestone in her successful career in healthcare.

More than half (53%) of patients reached remission after one year of Omvoh treatment and 46% experienced healing of the ...

The GLP-1 [glucagon-like peptide 1] agents are poised to become viable options for treating indications beyond type 2 ...